- Home
- BDTX vs AGEN Comparison
BDTX vs AGEN Comparison
Compare BDTX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- AGEN
- Stock Information
- Founded
- BDTX 2014
- AGEN 1994
- Country
- BDTX United States
- AGEN United States
- Employees
- BDTX N/A
- AGEN N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BDTX Health Care
- AGEN Health Care
- Exchange
- BDTX Nasdaq
- AGEN Nasdaq
- Market Cap
- BDTX 132.5M
- AGEN 87.7M
- IPO Year
- BDTX 2020
- AGEN 2000
- Fundamental
- Price
- BDTX $2.61
- AGEN $5.26
- Analyst Decision
- BDTX Strong Buy
- AGEN Buy
- Analyst Count
- BDTX 6
- AGEN 4
- Target Price
- BDTX $14.83
- AGEN $13.00
- AVG Volume (30 Days)
- BDTX 1.2M
- AGEN 1.1M
- Earning Date
- BDTX 08-05-2025
- AGEN 08-07-2025
- Dividend Yield
- BDTX N/A
- AGEN N/A
- EPS Growth
- BDTX N/A
- AGEN N/A
- EPS
- BDTX 0.09
- AGEN N/A
- Revenue
- BDTX $70,000,000.00
- AGEN $99,524,000.00
- Revenue This Year
- BDTX N/A
- AGEN $12.69
- Revenue Next Year
- BDTX N/A
- AGEN N/A
- P/E Ratio
- BDTX $28.49
- AGEN N/A
- Revenue Growth
- BDTX N/A
- AGEN N/A
- 52 Week Low
- BDTX $1.20
- AGEN $1.38
- 52 Week High
- BDTX $6.75
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- BDTX 59.61
- AGEN 53.94
- Support Level
- BDTX $2.43
- AGEN $4.78
- Resistance Level
- BDTX $2.72
- AGEN $6.20
- Average True Range (ATR)
- BDTX 0.17
- AGEN 0.52
- MACD
- BDTX -0.01
- AGEN -0.04
- Stochastic Oscillator
- BDTX 75.77
- AGEN 42.20
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).